TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT07639879
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-07-30Est. Completion: 2029-07-30
Enrollment target: 180 participants Locations- Peking University Cancer Hospital, Beijin, Beijing Municipality, China
Other microbiome trials you might be interested in
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAnaplastic Large Cell LymphomaMycosis FungoidesRelapsed Anaplastic Large Cell LymphomaRelapsed Mycosis Fungoides
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the h…
Scottsdale, United StatesEst. completion Dec 31, 2028
B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Mycosis FungoidesRecurrent Plasma Cell MyelomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Acute Myeloid LeukemiaRefractory Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Plasma Cell MyelomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide …
Scottsdale, United StatesEst. completion Dec 31, 2028